Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
Merus B.V.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
M.D. Anderson Cancer Center
University of Kentucky
University of California, San Diego
Groupe Oncologie Radiotherapie Tete et Cou
DEKA Biosciences
Sun Yat-sen University